Key result
A 65-year-old male developed atrial fibrillation with rapid ventricular rate after receiving a single dose of intravenous cyclophosphamide, well below the typical cardiotoxic threshold.
Case Report (n=1)
A single, low dose of cyclophosphamide can induce atrial fibrillation with rapid ventricular rate, highlighting the need for monitoring in patients with predisposing factors like renal insufficiency and concomitant steroid use.
Answers are grounded in this paper and cite their sources.
Low-dose cyclophosphamide may trigger AF in susceptible patients; leaves open whether enhanced monitoring is needed beyond current practice.
Cyclophosphamide (CYA), also known as cytophosphane, is a medication used as a chemotherapeutic agent and immune suppressor.Its common adverse effects include nausea, vomiting, diarrhea, bone marrow suppression, hemorrhagic cystitis, alopecia, lethargy, and cardiotoxicity. Cyclophosphamide-related cardiac toxicity is not uncommon and causes potentially serious complications in patients. In this review, we present a case of a 65-years-old patient who developed atrial fibrillation with rapid ventricular rate (RVR) after receiving a single dose of CYA. In this case, the advanced age of the patient, pre-treatment with prednisone, and renal insufficiency most likely predisposed the patient to CYA-induced cardiac toxicity. A relevant literature review was also conducted to determine the pathogenesis, risk factors, and spectrum of CYA-induced cardiac toxicity.
No takes yet. Share an insight, caveat, or question.
Ejaz et al. (2018) conducted a case report in Focal necrotizing glomerulonephritis (n=1). Cyclophosphamide was evaluated on Development of atrial fibrillation with rapid ventricular rate. A 65-year-old male developed atrial fibrillation with rapid ventricular rate after receiving a single dose of intravenous cyclophosphamide, well below the typical cardiotoxic threshold.
Synapse has enriched 10 related papers. Consider them for comparative context: